After many years of pioneering activities in cell and gene therapy with some ups and many downs, the field accelerated all of a sudden with a number of major industry and investor activities.
A strong driver for these deals has been the development of CAR-T technology, enabling T-cells to be directed to kill any cells that express a particular antigen. This has proven to achieve long-lasting clinical effects in certain hematologic malignancies, while more development is needed to successfully apply CAR-T cell therapy to solid tumor settings. The attractiveness of the T-cell approach is clearly the potential of having complete and durable responses after a single treatment, with long-living T-cells providing immune surveillance including across the blood brain barrier.
It is in this turmoil of industry and investment activity that makes discussing the many challenges involved in the development, testing, production and registration of ATMPs as important and vital as ever.
The PDA Europe Scientific Program Planning Committee has worked diligently once again to provide you with top representatives of governments, industry, and academia, active in this highly promising field as well as cell and gene therapy. They will share with us their latest knowledge and experience regarding medical, therapeutic and regulatory developments, the technologies involved, and they will lend key insights into best practice approaches.
We warmly welcome you to become part of this group of great people, join us on this amazing journey and encourage you to get involved in this unique and highly professional discussion forum!